KalVista Pharmaceuticals (KALV) EPS (Weighted Average and Diluted) Growth (1y) (2021 - 2025)
KalVista Pharmaceuticals (KALV) EPS (Weighted Average and Diluted) Growth (1y) (2021 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
814,307.08 Bn |
814,307.05 Bn |
- |
- |
| 2 |
Belite Bio |
55,320.00 Bn |
55,320.00 Bn |
- |
251.11% |
| 3 |
Quantum Biopharma |
17,149.72 Bn |
17,149.72 Bn |
- |
-13.31% |
| 4 |
Legend Biotech |
3,590.00 Bn |
3,589.71 Bn |
242.10 Mn |
102.51% |
| 5 |
Akari Therapeutics |
1,650.72 Bn |
1,650.72 Bn |
- |
-79.34% |
| 6 |
Evaxion A |
1,522.09 Bn |
1,522.07 Bn |
- |
- |
| 7 |
Psyence Biomedical |
229.39 Bn |
229.38 Bn |
- |
-103.05% |
| 8 |
Vertex Pharmaceuticals |
113.09 Bn |
105.85 Bn |
2.59 Bn |
61.45% |
| 9 |
Abivax |
90.15 Bn |
90.15 Bn |
- |
- |
| 10 |
KalVista Pharmaceuticals |
1.44 Bn |
1.25 Bn |
56.41 Mn |
-28.74% |
| Date | Value |
|---|
| Jul 31, 2025 |
-28.74% |
| Apr 30, 2025 |
7.48% |
| Oct 31, 2024 |
-13.75% |
| Jul 31, 2024 |
-17.57% |
| Apr 30, 2024 |
-42.67% |
| Jan 31, 2024 |
-12.00% |
| Oct 31, 2023 |
11.11% |
| Jul 31, 2023 |
21.28% |
| Apr 30, 2023 |
23.47% |
| Jan 31, 2023 |
18.48% |
| Oct 31, 2022 |
-12.50% |
| Jul 31, 2022 |
-42.42% |
| Apr 30, 2022 |
-5.55% |
| Apr 30, 2021 |
-91.74% |
